TCS-1205
TCS-1205's theme is one that has captured the attention of people of all ages and backgrounds. From its relevance in modern society to its impact on history, TCS-1205 has been the subject of debate and reflection in numerous areas. Over the years, different perspectives and approaches have emerged, enriching the understanding and appreciation of TCS-1205. In this article, we will explore various facets of TCS-1205, from its origins to its current influence, with the aim of providing a broad and complete overview of this fascinating topic.
 | |
| Names | |
|---|---|
| IUPAC name
2-(5-Nitro-1H-indol-3-yl)-2-oxo-N-acetamide
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| |
| |
| Properties | |
| C18H15N3O4 | |
| Molar mass | 337.335 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).
| |
TCS 1205 is a GABAA receptor positive allosteric modulator of the tryptamine family. It is a benzodiazepine site agonist selective for certain subunits.
Pharmacology
TCS 1205 acts at the benzodiazepine binding site, it is selective for the α1 and α2 subunits of the GABAA receptor.[1] In vivo, it has anxiolytic effects but no sedative effects.[2][3]
Chemistry
Despite acting at the benzodiazepine receptor, it does not contain the benzodiazepine structure, it could therefore be classed as a nonbenzodiazepine. The drug is a substituted tryptamine derivative.
References
- ^ "TCS 1205" (PDF). Certificate of Analysis. Tocris Bioscience.
- ^ "TCS 1205". AbMole BioScience.
- ^ Taliani S, Cosimelli B, Da Settimo F, Marini AM, La Motta C, Simorini F, et al. (June 2009). "Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the gamma-aminobutyric acid-A (GABAA) alpha2 benzodiazepine receptor". Journal of Medicinal Chemistry. 52 (12): 3723–3734. doi:10.1021/jm9001154. PMID 19469479.